• Obeticholic Acid: Optimizing Liver Fibrosis Models with FXR

  2026-07-06

  Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid) is redefining hepatic fibrosis research through potent FXR agonism, enabling precise modulation of gene expression and immunometabolic pathways. This guide delivers actionable protocols, troubleshooting strategies, and a translation of recent mechanistic breakthroughs for advanced MASLD and portal hypertension models.

• ATP Solution (100 mM): Enabling Robust mRNA-LNP Therapeutic

  2026-07-06

  Explore how ATP Solution (100 mM) empowers advanced mRNA-LNP cancer research, with a special focus on assay reliability and translational relevance. This article offers a deep dive into ATP’s mechanistic roles and practical protocol design, setting it apart from existing guides.

• Dovitinib (TKI-258): Optimizing RTK Inhibition in Cancer Res

  2026-07-05

  Dovitinib (TKI-258) uniquely empowers researchers to dissect and manipulate receptor tyrosine kinase signaling across diverse cancer models, with robust performance in apoptosis induction and pathway analysis. This guide details hands-on workflows, troubleshooting, and integration strategies for maximizing the impact of APExBIO’s Dovitinib in translational oncology.

• Structural Variants of Cyclosporin and Mitochondrial Pore In

  2026-07-04

  This study systematically compares cyclosporin B–E variants, focusing on their structural flexibility and functional capacity to inhibit the mitochondrial permeability transition pore. Using NMR and molecular dynamics, the research clarifies why only cyclosporin A-like conformations retain potent mitochondrial and immunosuppressive activity, informing both mechanistic understanding and experimental design.

• tFUS Attenuates Stroke-Induced Neuroinflammation via Nespas/

  2026-07-03

  This study demonstrates that transcranial focused ultrasound stimulation (tFUS) reduces neuroinflammation following ischemic stroke by modulating the Nespas/miR-383-3p/SHP2 signaling pathway. The findings reveal a mechanistic link between noninvasive neuromodulation and suppression of NLRP3 inflammasome activity, suggesting new therapeutic avenues for post-stroke intervention.

• Evaluating Fumagillin’s Efficacy Against Azumiobodo hoyamush

  2026-07-03

  This study systematically assesses the in vitro and in vivo efficacy of Fumagillin and other antiprotozoal agents against Azumiobodo hoyamushi, the causative agent of soft tunic syndrome in Halocynthia roretzi. Findings clarify Fumagillin’s moderate antiparasitic potency and inform future disease management strategies in aquaculture.

• Tofacitinib (CP-690550): Bridging Immune Modulation and Mito

  2026-07-02

  This thought-leadership article delivers a mechanistic and strategic roadmap for translational researchers leveraging Tofacitinib (CP-690550) in rheumatoid arthritis (RA) macrophage models. By synthesizing cutting-edge insights into JAK/STAT signaling, cytokine blockade, and mitochondrial repair, and drawing from recent landmark research, it establishes new experimental and translational guidance. The discussion transcends traditional product pages by integrating evidence-based protocol parameters, highlighting competitive limitations, and articulating forward-looking implications for immune modulation research.

• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Precision CDK

  2026-07-02

  Explore how 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) enables precise modulation of the cyclin-dependent kinase signaling pathway and RNA polymerase II activity. This article delivers a deeper, application-driven analysis of DRB’s mechanistic strengths and practical protocols for advanced transcriptional research.

• Molidustat (BAY85-3934): Redefining Renal Anemia via HIF Sta

  2026-07-01

  Discover how Molidustat (BAY85-3934) advances renal anemia therapy by precisely stabilizing hypoxia-inducible factors. This article uniquely explores the intersection of HIF-PH inhibition, erythropoietin modulation, and the translational relevance of recent mechanistic insights.

• Prochlorperazine in Melanoma: Mechanisms, Validation, and Vi

  2026-07-01

  Explore how Prochlorperazine—a dopamine D2 receptor antagonist—reshapes the landscape of melanoma research with mechanistic depth, actionable protocols, and translational insight. This thought-leadership article integrates new experimental findings, cross-domain relevance, and strategic guidance for researchers at the intersection of oncology, antiemetic therapy, and antiviral innovation.

• Validated Apoptosis Detection: One-step TUNEL Cy3 Kit (K1134

  2026-06-30

  This article addresses key challenges in apoptosis detection workflows using the One-step TUNEL Cy3 Apoptosis Detection Kit (SKU K1134). Through scenario-driven Q&A, we examine real lab issues, protocol optimization, and data reliability, backed by experimental models and peer-reviewed findings. Explore how SKU K1134 empowers accurate and reproducible DNA fragmentation assays in both cell and tissue contexts.

• T. spiralis ESP Induces Gut Barrier Apoptosis: New Mechanist

  2026-06-30

  Lu et al. (2025) reveal that Trichinella spiralis excretory/secretory proteins (ESP) disrupt gut epithelial barriers by inducing apoptosis in enterocytes, facilitating larval invasion. Their work establishes caspase-dependent apoptosis as a mechanistic driver and demonstrates the utility of caspase inhibition to restore barrier integrity in vitro.

• RIPA Lysis Buffer (Strong): Precision Protein Extraction for

  2026-06-29

  Discover how RIPA Lysis Buffer (Strong) enables advanced protein extraction for dissecting blood-brain barrier (BBB) and neuroimmune interactions. This cornerstone article offers a unique focus on assay decision-making and mechanistic rigor, exceeding standard protocol coverage.

• Chenodeoxycholic Acid in FXR-Driven Renal and Metabolic Rese

  2026-06-29

  Chenodeoxycholic Acid (CDCA) offers precision activation of FXR, unlocking new pathways for modeling kidney injury and cholesterol metabolism. Recent studies highlight its unique ability to upregulate KLF11 and suppress pro-inflammatory cascades, making it a cornerstone for advanced nuclear receptor signaling research.

• Exendin-4 (Exenatide): Practical Workflows for Type 2 Diabet

  2026-06-28

  Exendin-4, a potent GLP-1 receptor agonist, is redefining in vitro and in vivo type 2 diabetes research workflows by enabling precise modeling of insulin sensitivity, beta cell function, and hepatic steatosis reversal. Recent advances in recombinant yeast-based production and optimized protocol parameters further expand its utility for translational and mechanistic studies.

15931 records 1/1063 page Next 12345 下5页 Last page